NYSE$CRL
Charles River Laboratories International Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Revenue increased by 10.4% and GAAP earnings per share decreased by 6.5%.
Charles River Laboratories reported third-quarter results with revenue of $989.2 million, a 10.4% increase year-over-year. GAAP earnings per share were $1.88, a decrease of 6.5% from the prior year, while non-GAAP earnings per share were $2.63, a decrease of 2.6%. The company narrowed its 2022 revenue growth and earnings per share guidance and announced a planned divestiture of its Avian Vaccine business.
- Third-quarter revenue was $989.2 million, an increase of 10.4% from $895.9 million in the third quarter of 2021.
- GAAP earnings per share were $1.88, a decrease of 6.5% from $2.01 for the third quarter of 2021.
- Non-GAAP earnings per share were $2.63, a decrease of 2.6% from $2.70 per share for the third quarter of 2021.
- Company narrowed 2022 revenue growth and earnings per share guidance.
Headline financials
Revenue & EPS history
Charles River Labs · Revenue · Quarterly
$989M
Revenue by segment
Charles River Labs · $989M total across 3 segments · Q3 2022
- Discovery & Safety Assessment$619M+16.5%62.6%
- Manufacturing Solutions$190M-1.7%19.2%
- Research Models & Services$180M+5.2%18.2%
Forward guidance
The Company is updating 2022 financial guidance, which was previously provided on August 3, 2022. Revenue growth and non-GAAP earnings per share guidance are being narrowed to the upper end of the prior ranges, reflecting the solid, third-quarter performance. GAAP earnings per share guidance is being narrowed to the low end of the prior range, primarily as a result of contingent consideration adjustments related to the CDMO Sweden divestiture.
Tailwinds
- Revenue growth, reported: 10.0% – 11.0%
- Revenue growth, organic: 11.0% – 12.0%
- GAAP EPS: $7.90 – $8.05
- Non-GAAP EPS: $10.80 – $10.95
- Cash flow from operating activities: ~$700 million
Headwinds
- Contribution from acquisitions/divestitures, net: ~(1.0%)
- Impact of 53rd week in 2022: ~(1.5)%
- Unfavorable/(favorable) impact of foreign exchange: ~3.5%
- Acquisition-related amortization: ~$2.20
- Capital expenditures: ~$340 million
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+0.1%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+0.7%
Avg return
30 days after
47%
32 / 68 earnings
Positive
+18.4%
Q1 2025
Best reaction
-13.3%
Q3 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.8% | -9.0% | -0.1% | |
| Q4 2025 | -1.8% | +3.1% | -3.1% | |
| Q3 2025 | -5.5% | -5.0% | +3.6% | |
| Q1 2025 | +18.4% | +24.0% | +25.4% | |
| Q4 2024 | +6.9% | +10.4% | +8.3% | |
| Q3 2024 | +11.5% | +17.0% | +1.7% | |
| Q2 2024 | -11.7% | -15.1% | -17.8% | |
| Q1 2024 | -3.0% | -1.0% | -8.7% | |
| Q4 2023 | +11.4% | +11.2% | +17.6% | |
| Q3 2023 | -7.3% | -7.0% | +11.8% | |
| Q2 2023 | +5.5% | +5.2% | -3.2% | |
| Q1 2023 | +2.7% | +1.0% | +6.1% | |
| Q4 2022 | -6.7% | -9.0% | -20.4% | |
| Q3 2022 | +4.8% | +9.0% | +7.4% | |
| Q2 2022 | -6.6% | -9.4% | -17.8% | |
| Q1 2022 | -1.2% | -8.9% | -3.3% | |
| Q4 2021 | -6.7% | -6.1% | -8.3% | |
| Q3 2021 | -12.2% | -13.4% | -17.3% | |
| Q2 2021 | -0.3% | -0.4% | +9.3% | |
| Q1 2021 | +4.0% | +3.2% | -0.1% | |
| Q4 2020 | +2.0% | -1.1% | -0.0% | |
| Q3 2020 | +2.6% | +7.0% | +3.7% | |
| Q2 2020 | +6.8% | +7.3% | +0.4% | |
| Q1 2020 | +11.1% | +12.0% | +24.2% | |
| Q4 2019 | +8.6% | +11.9% | -21.3% | |
| Q3 2019 | -2.5% | +1.1% | +12.0% | |
| Q2 2019 | -5.1% | -10.3% | -7.0% | |
| Q1 2019 | -4.2% | -4.1% | -10.4% | |
| Q4 2018 | +8.1% | +9.0% | +11.1% | |
| Q3 2018 | +8.8% | +6.8% | +3.0% | |
| Q2 2018 | -5.2% | -6.6% | -1.6% | |
| Q1 2018 | +0.3% | -1.0% | +8.5% | |
| Q4 2017 | +8.2% | +6.0% | +9.9% | |
| Q3 2017 | -13.3% | -14.3% | -11.9% | |
| Q2 2017 | -1.7% | -0.2% | +10.0% | |
| Q1 2017 | -3.8% | -2.3% | +2.8% | |
| Q4 2016 | +7.6% | +7.3% | +8.4% | |
| Q3 2016 | -9.0% | -5.1% | -3.0% | |
| Q2 2016 | -0.0% | -3.1% | -3.0% | |
| Q1 2016 | +2.5% | — | — | |
| Q4 2015 | +3.9% | — | — | |
| Q3 2015 | +5.7% | — | — | |
| Q2 2015 | +1.4% | — | — | |
| Q1 2015 | -8.8% | — | — | |
| Q4 2014 | +6.3% | — | — | |
| Q3 2014 | -1.9% | — | — | |
| Q2 2014 | +6.0% | — | — | |
| Q1 2014 | -6.6% | — | — | |
| Q4 2013 | -1.6% | — | — | |
| Q3 2013 | -1.2% | — | — | |
| Q2 2013 | +3.4% | — | — | |
| Q1 2013 | -3.9% | — | — | |
| Q4 2012 | +0.9% | — | — | |
| Q3 2012 | -5.3% | — | — | |
| Q2 2012 | +2.3% | — | — | |
| Q1 2012 | +1.8% | — | — | |
| Q4 2010 | -1.3% | — | — | |
| Q4 2011 | -1.3% | — | — | |
| Q3 2011 | -5.0% | — | — | |
| Q2 2011 | -9.4% | — | — | |
| Q1 2010 | -2.4% | — | — | |
| Q1 2011 | -0.1% | — | — | |
| Q4 2008 | -0.9% | — | — | |
| Q3 2010 | -4.4% | — | — | |
| Q3 2009 | -4.4% | — | — | |
| Q2 2010 | +3.6% | — | — | |
| Q4 2009 | +3.6% | — | — | |
| Q2 2009 | +3.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro